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Although opioids have been extensively studied for their impact on the immune system,
limited information is available about the specific actions of opioids on intracellular
antiviral innate immunity against HIV infection. Thus, we investigated whether heroin,
one of the most abused drugs, inhibits the expression of intracellular HIV restriction
microRNA (miRNA) and facilitates HIV replication in macrophages. Heroin treatment of
macrophages enhanced HIV replication, which was associated with the downregulation
of several HIV restriction miRNAs. These heroin-mediated actions on the miRNAs and
HIV could be antagonized by naltrexone, an opioid receptor antagonist. Furthermore,
the in vitro negative impact of heroin on HIV-associated miRNAs was confirmed by the
in vivo observation that heroin addicts had significantly lower levels of macrophage-
derived HIV restriction miRNAs than those in the control subjects. These in vitro
and in vivo findings indicate that heroin use compromises intracellular anti-HIV innate
immunity, providing a favorable microenvironment for HIV survival in the target cells.
Keywords: Heroin, HIV, IFN-α/β, miRNAs, macrophage
INTRODUCTION
Injection drug users (IDUs) now represent one of the largest reservoirs of HIV infection in the
United States, contributing to the fastest spread of the virus (Alcabes and Friedland, 1995; Risdahl
et al., 1998). IDUs frequently use heroin, the most commonly abused opiate (Martin et al., 2010).
Opiate use is associated with the worst health outcomes in HIV-infected individuals, as they
adversely impact the human immune system. Clinical and epidemiological evidence from pre-
AIDS studies indicate that opiates (particular heroin) play a cofactor role in the pathogenesis of
HIV infection (Donahoe et al., 1993; Ronald et al., 1994; Specter, 1994; Meijerink et al., 2015;
Zhou et al., 2015). In vitro studies from diﬀerent laboratories also provide direct evidence that
opiates (morphine) facilitate HIV infection of the target cells. Morphine enhanced HIV replication
in human monocytes/macrophages (Guo et al., 2002; Ho et al., 2003; Li et al., 2003; Wang et al.,
2011a), T lymphocytes (Chuang et al., 1993; Steele et al., 2003; Peterson et al., 2004), kupﬀer cells
(Schweitzer et al., 1991), human neuroblastoma cells (Squinto et al., 1990), and human brain cells
(Chao et al., 1995; Peterson et al., 1999; Reynolds et al., 2006).
The enhancing eﬀect of opiates on HIV is likely due to their negative impact on the host
immune defense mechanisms. Opiates are known to have a profound eﬀect on the immune system
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FIGURE 1 | Heroin enhances HIV infection of macrophages. (A) Seven-day cultured macrophages were incubated with or without heroin at indicated
concentrations for 6 h prior to different HIV strain (Bal, JRFL, or JAGO) infection. HIV RT activity was determined at day 12 postinfection. (B) Seven day cultured
macrophages were incubated with or without heroin at the indicated concentrations for 6 h prior to HIV (Bal) infection. HIV RT activity was determined at day 6, 10,
and 12 postinfection. Cell culture supernatant was collected at the indicated time points and subjected to RT assay to detect HIV RT activity. The data shown is the
mean ± SD of triplicate cultures representative of three experiments using cells from three different donors (∗p < 0.05, ∗∗p < 0.01, heroin vs. control).
(Wang and Ho, 2011; Wang et al., 2011b; Samikkannu et al.,
2015). To date, the immunosuppressive eﬀects of opiates have
been extensively investigated in the major cell types of the
immune system, including natural killer cells, T cells, B cells,
macrophages and polymorphonuclear leukocytes (Brack et al.,
2011; Eisenstein, 2011; Boland et al., 2014; Pomorska et al.,
2014). Macrophages, as a primary target of HIV infection, are
among the ﬁrst cells infected by HIV and late function as
a reservoir for the virus. Although opioids have been shown
to modulate the function of macrophages, there is limited
information about the speciﬁc actions of opiates, particularly
heroin, on intracellular antiviral innate immunity that controls
HIV replication in macrophages. Earlier studies reported that
morphine suppressed the production of type I interferons (IFNs;
Peterson et al., 1989; Wang et al., 2002), the key cytokines that
modulate all phases of immune processes and play a central role
in host innate immunity against viral infections. In response to
viral infections, IFN-α/β can trigger down-stream cell signaling
and subsequent induction of many IFN-stimulated genes (ISGs)
and other antiviral factor. IFN-α/β also induce antiviral miRNAs
(Pedersen et al., 2007; Zhou et al., 2010; Cobos Jimenez et al.,
2012). Studies have demonstrated that the miRNAs participate
in the host immune responses to viral infections, including HIV
(Huang et al., 2007; Wang et al., 2009; Kumar, 2011). In general,
the miRNAs interfere with HIV replication by either directly
binding to viral RNAs or targeting the cellular factors that are
related to HIV survival (Huang et al., 2007; Klase et al., 2012;
Chen et al., 2014). Several cellular miRNAs (miR-28, 29a, 125b,
150, 198, 223, and 382) have been identiﬁed to target a set of
accessory genes of HIV (Hariharan et al., 2005; Ahluwalia et al.,
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FIGURE 2 | Naltrexone blocks the heroin-mediated enhancement of
HIV. Seven-day cultured macrophages were incubated with or without heroin
at the indicated concentrations for 6 h prior to HIV Bal, JRFL, or JAGO
infection. Naltrexone (10−6 M) was added to the macrophages cultures for
1 h prior to heroin (10−7 M) treatment. HIV RT activity was determined at day
12 postinfection. Cell culture supernatant was collected at the indicated time
points and subjected to RT assay to detect the HIV RT activity. The data
shown is the mean ± SD of triplicate cultures representative of three
experiments using cells from three different donors (∗∗p < 0.01, heroin vs.
heroin + naltrexone).
2008; Nathans et al., 2009; Sung and Rice, 2009; Wang et al.,
2009). For example, these HIV restriction miRNAs can target
the 3′UTR of HIV transcripts, potentially rendering productive
infection of HIV into latency in resting CD4+ T lymphocytes
(Huang et al., 2007).We reported thatmonocytes from peripheral
blood are enriched with some of these HIV restriction miRNA,
which contribute to the resistance of monocytes to HIV infection
(Wang et al., 2009). Given the key role of the HIV restriction
miRNAs in intracellular innate immunity, it is of signiﬁcance to
determine whether environmental factors such as heroin abuse
can dysregulate these miRNAs in the target cells of HIV.
MATERIALS AND METHODS
Study Subjects
Fourteen heroin addicts and eight control subjects were recruited
by the Wuhan Center for Disease Prevention and Control
(Wuhan CDC) in China. Informed consent was obtained from
the study subjects, and the Institutional Research Board of
the Wuhan CDC approved this study. The majority (>80%)
of heroin users in China use heroin only (Lu et al., 2008).
Polydrug use was excluded based on the self-report and Urine
Screen. All the subjects were current heroin users as their
urine tests were positive for opiate at the time of enrollment.
The control subjects were recruited using convenience sampling
from the community in which the study site was located.
Subjects were excluded if they had a chronic systemic illness
FIGURE 3 | Heroin inhibits HIV restriction miRNAs. (A) Effect of heroin on
miRNA expression in macrophages. Seven-day cultured macrophages were
cultured in the presence or absence of heroin at the indicated concentration
(10−7 M) for 6 h. Total cellular RNA was then extracted from cell cultures and
subjected to real-time RT-PCR for miRNA-28, miRNA-125b, miRNA-150,
miRNA-382, miRNA-223, miRNA-122, miRNA-124a, and Let-7c expression.
Data is given as a mean ± SD of triplicate cultures representative of three
experiments using cells from three different donors (∗P < 0.05, ∗∗P < 0.01 for
heroin vs. control). (B) Seven-day cultured macrophages were incubated in
the presence or absence of heroin at the indicated concentrations for 6 h.
Total cellular RNA extracted from cell cultures was subjected to realtime
RT-PCR for miRNA expression, miRNA-28, miRNA-125b, miRNA-150, and
miRNA-382. The data shown is the mean ± SD of triplicate cultures
representative of three experiments using cells from three different donors
(∗p < 0.05, ∗∗p < 0.01, heroin vs. control).
(cardiac, renal, pulmonary, hepatic, endocrine, metabolic, or
autoimmune disorders), major psychiatric disorders or if they
were abusing other substances other than heroin (urine drug
test). Control subjects with no history of drug or alcohol abuse
were also excluded if they had major medical or psychiatric
disorders. All the study subjects were negative for HIV and
HCV.
Cell Isolation and Culture
Peripheral blood samples were obtained from healthy adult
donors without a known history of drug abuse, and identiﬁed
as HIV-1 antibody negative. Monocytes were puriﬁed as per
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FIGURE 4 | Naltrexone blocks the heroin action on HIV restriction miRNAs. Naltrexone (10−6 M) was added to macrophage cultures for 1 h prior to heroin
treatment. Total cellular RNA was then extracted from the cell cultures 6 h post-treatment and subjected to realtime RT-PCR for miRNA expression: miRNA-28 (A),
miRNA-125b (B), miRNA-150 (C), and miRNA-382 (D). The data shown is the mean ± SD of triplicate cultures representative of three experiments using cells from
three different donors (∗p < 0.05, ∗∗p < 0.01, heroin vs. control, or heroin + naltrexone).
the previously described technique (Wang et al., 2009, 2011a).
In brief, heparinized blood is separated by centrifugation over
Lymphocyte Separation Medium at 400–500Xg for 45 min.
The mononuclear layer is collected and incubated with
Dulbecco’s Modiﬁed Eagle’s Medium (DMEM) in 2% gelatin-
coated ﬂasks for 45 min at 37◦C, followed by removal of
the non-adherent cells with DMEM. Following the initial
puriﬁcation, at least 97% of the cells are monocytes, as
determined by ﬂow cytometry analysis using a monoclonal
antibody against CD14, a marker speciﬁc for monocytes and
macrophages. Puriﬁed monocytes are plated in 48-well culture
plates (0.25 × 106 cells/well) or 96-well culture plates (105
cells/well) in DMEM containing 10% fetal calf serum (FCS) for
7 days. Monocyte-derived macrophages (MDMs) refer to 7-days-
cultured macrophages.
RNA Extraction and Real-time RT-PCR
Total cellular RNA, including miRNA, was extracted from the
cells using the miRNeasy Mini Kit from QIAGEN (Valencia,
CA, USA). Total RNA (1μg) was reverse-transcribed with
the miScript Reverse Transcription Kit from QIAGEN. Real-
time RT PCR for the quantiﬁcation of a subset of miRNAs
(miRNA-28, miRNA-125b, miRNA-150, miRNA-382, miRNA-
223, miRNA-122, Let-7c, and miRNA-124a) was carried out
with miScript Primer Assays and the miScript SYBR Green
PCR Kit from QIAGEN as described (Wang et al., 2009).
For mRNA detection, the resulting cDNA was then used as a
template for real-time PCR quantiﬁcation. Real-time PCR was
performed with 1/10 of the cDNA with speciﬁc primers for the
quantiﬁcation of IFN-α/β, and GAPDH gene expression with
the iQ SYBR Green Supermix (Bio-Rad Laboratories, Hercules,
FIGURE 5 | Heroin inhibits IFN-α and IFN-β. Naltrexone (10−6 M) was added to the macrophage cultures for 1 h prior to heroin treatment. Total cellular RNA
was then extracted from the cell cultures 6 h post-treatment and subjected to realtime RT-PCR for IFN-α (A) and IFN-β (B) expression. The data shown is the
mean ± SD of triplicate cultures representative of three experiments using cells from three different donors (∗p < 0.05, ∗∗p < 0.01, heroin vs. control, or
heroin + naltrexone).
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FIGURE 6 | Heroin users have decreased levels of HIV restriction miRNAs. Total RNA was exacted from macrophages derived from monocytes of heroin
addicts and normal control subjects. miRNA-28 (A), miRNA-125b (B), miRNA-150 (C), miRNA-382 (D), and miRNA-223 (E) was amplified using specific primers
and quantified by real time RT-PCR. The results are expressed as relative transcript abundance of miRNA/GAPDH.
CA) (Zhou et al., 2009, 2010). The oligonucleotide primers were
synthesized by Integrated DNA Technologies, Inc. (Coralville,
IA). The speciﬁc oligonucleotide primers used wereas follows:
IFN-α:5′-TTTCTCCTGCCTGAAGGAC-AGAG-3′ (sense) and
5′-GCTCATGATTTCTGCTCTGACA-3′ (antisense) (Tsutsumi
et al., 1999); IFN-β: 5′-GCCGCATTGACCATCTATGAGA-
3′ (sense) and 5′-GAGATCTTCAGTTTCGGAGG-TAAC-3′
(antisense); GAPDH (the house keeping gene):5′- GGTGGTCT
CCTCTGACTTCAACA-3′ (sense) and 5′-GTTGCTGTAGCCA
AATTCGTTGT-3′ (anti-sense). The IFN-α primer pair matches
11 IFN-α subtypes: IFNA2, IFNA4, IFNA5, IFNA6, IFNA7,
IFNA8, IFNA10, IFNA14, IFNA16, IFNA17, and IFNA21.
HIV Strains and Other Reagents
Based on their diﬀerential use of the major HIV receptors (CCR5
and CXCR4), HIV isolates can be classiﬁed to R5, X4, and R5X4
strains (Berger et al., 1998). HIV Bal and JRFL strains (R5 tropic)
were obtained from the AIDS Research and Reference Reagent
Program at the NIH (Bethesda, MD, USA). HIV JAGO strain
(R5 tropic) was obtained from the Center for AIDS Research at
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the School of Medicine, University of Pennsylvania. Heroin was
kindly provided by Dr. Martin Adler from Temple University,
Center for Substance Abuse Research through the NIDA drug
supply program. Naltrexone was obtained from Sigma (St Louis,
MO, USA).
Heroin and/or Naltrexone Treatment
Seven-days-cultured macrophages (105 cells/well in 96-well
plates, or 2.5 × 105 cells/well in 48-well plates) with or without
heroin were incubated at diﬀerent concentrations (10−9M to
10−6M) for 6 h. The selection of these concentrations of heroin
was based on studies by others (Wang et al., 2002; Reynolds
et al., 2006) and us (Guo et al., 2002; Wang et al., 2005, 2012).
To investigate whether naltrexone blocks the heroin action,
we treated the macrophages for 1 h with naltrexone (10−6M),
followed by heroin treatment.
Infection of Macrophages with HIV
Seven-days-cultured macrophages were infected with equal
amounts of cell-free HIV Bal, JAGO, or JRFL strain for 2 h
at 37◦C after treatment with or without heroin. Cells were
then washed three times with plain DMEM, to remove any
unabsorbed virus, and fresh media containing heroin and/or
naltrexone was added to the cell culture. Untreated cell served
as a control. Culture supernatant was harvested at day 6, 10, and
12 postinfection for RT assay.
HIV RT Assay
HIV RT activity was determined based on the technique (Willey
et al., 1988) with modiﬁcations (Ho et al., 1992). In brief, 10 μl of
culture supernatant from macrophages infected with or without
HIV was added to a cocktail containing poly(A), oligo(dT)
(Amersham Biosciences, Inc., Piscataway, NJ, USA), MgCl2, and
[32P]dTTP (AmershamBiosciences, Inc.), and incubated for 24 h
at 37◦C. 30 μl of the cocktail was spotted onto DE81 paper
(Whatman Internatianl Ltd, England), then dried and washed
ﬁve times with 2 x saline-sodium citrate buﬀer and once with
95% ethanol. The ﬁlter paper was then air-dried. Radioactivity
was counted in a liquid scintillation counter (PerkinElmer Life
Sciences, Boston, MA, USA).
Statistical Analysis
A student’s t-test was used to evaluate the signiﬁcance of the
diﬀerences between groups, and multiple comparisons were
performed by regression analysis and one-way analysis of
variance. Statistical analyses were performed with Graphpad
Instat Statistical Software (Graphpad Software Inc., San Diego,
CA, USA), and all data is presented as the mean ± SD. Statistical
signiﬁcance was deﬁned as P < 0.05.
RESULTS
Heroin Enhances HIV Infection of
Macrophages
We ﬁrst determined the dose eﬀect of heroin on HIV infection
of macrophages. Heroin treatment enhanced the susceptibility
of macrophages to infection with HIV Bal, JAGO, and JRFL
strains, as evidenced by increased RT activity at day 12
postinfection (Figure 1A). We also examined the time course
eﬀect of heroin treatment on HIV infection of macrophages.
As demonstrated in Figure 1B, heroin treatment increased HIV
RT activity at diﬀerent time points post infection. We further
examined the eﬀect of an opioid receptor antagonist on heroin-
mediated enhancement of HIV RT activity. The pretreatment of
macrophages with the opioid receptor antagonist (naltrexone)
completely abrogated the enhancing eﬀect of heroin on HIV RT
activity (Figure 2).
Heroin Inhibits HIV Restriction miRNAs
We ﬁrst examined whether heroin has the ability to suppress the
HIV restriction miRNAs in macrophages. As shown in Figure 3,
heroin treatment of macrophages inhibited the expression of four
HIV restriction miRNAs (miRNA-28, miRNA-125b, miRNA-150,
and miRNA-382). The highest inhibition by heroin was observed
at a concentration of 10−7M (Figure 3B). In contrast, heroin
treatment of macrophages had little eﬀect on the expression of
miRNA-223, miRNA-124a, Let-7c, and miRNA-122 (Figure 3A).
Since heroin-mediated enhancement of HIV infection could be
blocked by naltrexone (Figure 2), we examined the eﬀect of
naltrexone on heroin-mediated inhibition of anti-HIV factor
expression. As shown in Figure 4, naltrexone completely
abrogated the suppressing eﬀect of heroin on anti-HIV miRNA
expression, whereas naltrexone alone had little eﬀect on anti-HIV
miRNA expression (Figure 4).
Heroin Suppresses Type I IFNs
Type I IFNs (IFN-α/β) are well known for their ability to
inhibit a wide range of virus(s), including HIV. Although the
anti-HIV mechanism(s) of IFN-α/β remain to be determined,
many cellular factors including miRNAs have been identiﬁed
as IFN-α/β-inducible anti-HIV elements in target cells (Alter,
1999; Samuel, 2001; Sen, 2001; Okumura et al., 2006; Peng
et al., 2006; Huang et al., 2007; Mosoian et al., 2007; Neil
et al., 2008; Randall and Goodbourn, 2008; Van Damme et al.,
2008; Wang et al., 2008). We thus examined whether heroin
can suppress intracellular IFN-α and IFN-β expression in
macrophages. As shown in Figures 5A,B, heroin treatment
of macrophages, signiﬁcantly suppressed IFN-α and IFN-β
expression. The pretreatment of macrophages with naltrexone
could block the eﬀect of heroin on IFN-α and IFN-β expression
(Figures 5A,B).
In Vivo Impact of Heroin on HIV
Restriction miRNAs
In order to conﬁrm the in vitro action of heroin on the HIV
restriction miRNAs, we examined the levels of these miRNAs
in macrophages derived from monocytes of the heroin addicts
and control subjects. As shown in Figure 6, heroin addicts had
signiﬁcantly lower levels of the HIV restriction miRNAs (miRNA-
28, miRNA-125b, miRNA-150, andmiRNA-382) than the control
subjects. However, there was little diﬀerence in miRNA-223 levels
between heroin addicts and control subjects (Figure 6).
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DISCUSSION
Injection of heroin use increases the risk of acquiring HIV
(Friedman et al., 2003; Sagar et al., 2015) and progression
to AIDS (Ronald et al., 1994). However, because of the
complexity of opioid addiction and/or HIV infection, it has
been extremely diﬃcult to compare diﬀerent clinical and
epidemiological ﬁndings in studying the impact of opioids
on HIV disease progression (Donahoe et al., 2009). The
majority of in vitro studies have shown that morphine enhances
HIV infection of PBMC (Suzuki et al., 2002), CD4+ T cells
(Chuang et al., 1993; Steele et al., 2003; Peterson et al., 2004),
and macrophages (Guo et al., 2002; Li et al., 2002, 2003;
Ho et al., 2003; Wang et al., 2011a, 2012). In the present
study, we demonstrated for the ﬁrst time that in vitro heroin
treatment of macrophages increases HIV infection/replication
with diﬀerent strains (Figure 1). This eﬀect of heroin on HIV
was speciﬁc, as naltrexone could completely block the heroin
action (Figure 2). We reported that human immune cells,
including monocytes/macrophages, express functional μ opioid
receptors (Guo et al., 2002; Ho et al., 2003; Wang et al.,
2011a).
To understand the mechanism(s) of heroin action on HIV,
we examined whether heroin use has a negative impact on
the intracellular HIV-associated miRNAs. It is now known that
a number of cellular miRNAs participate in host cell innate
immunity against viral infections, including HIV. We were
particularly interested in miRNA-28, miRNA-125b, miRNA-150,
miRNA-223, and miR-382, as they can target the HIV RNA 3-
terminus (a highly conserved region of the virus), inhibiting
the translation of almost all HIV encoded proteins, including
Rev and Tat, the key players in HIV replication in CD4+ T
cells and macrophages (Hariharan et al., 2005). These miRNAs
are enriched in resting CD4+ T cells (Huang et al., 2007)
and monocytes (Wang et al., 2009), which contribute to the
intracellular immune defense against HIV. The ﬁnding that
heroin could inhibit the expression of the HIV restriction
miRNAs provides a plausible mechanism for heroin-mediated
enhancement of HIV infection of macrophages. Interestingly,
heroin appears to selectively inhibit the HIV restriction miRNAs.
We found that the inhibitory eﬀect of heroin was limited to
four of these miRNAs (miRNA-28, -125b, -150, and -382), while
miR-223 and miRNA-124a/Let-7c were not aﬀected by heroin
treatment (Figure 3A). miRNA-124a/let-7c is HIV replication
required miRNAs (Farberov et al., 2015), and miRNA-122 is a
HCV-supportive miRNA (Fukuhara et al., 2012; Masaki et al.,
2015).
These in vitro observations (Figures 3 and 4) were conﬁrmed
in our in vivo investigation, showing that macrophages derived
from monocytes of the heroin addicts had lower levels of four
HIV restriction miRNAs (miRNA-28, -125b, 150, and 382) than
those from the control subjects. Similarly, heroin use had little
eﬀect on miRNA-223 expression as compared to the control
groups (Figure 6). This observation could be due to the fact that
miRNA-223 is not an inducible miRNA by IFN-α/β. We reported
(Zhou et al., 2010) that although IFN-α/β could induce the
expression of the HIV restriction miRNAs (miRNA-28, miRNA-
125b, miRNA-150, and miRNA-382), they had little eﬀect on
miRNA-223 expression in macrophages.
The mechanism(s) of the heroin action on the HIV restriction
miRNAs remains to be determined. However, it is likely
that heroin-mediated suppression of type I IFNs is partially
responsible for the heroin action on the miRNAs. As a potent
inducer of antiviral activities, IFN-α/β plays a crucial role in host
cell innate immunity. IFN-α/β can directly induce the expression
of miRNAs that have antiviral activity. Our earlier study
demonstrated that IFN-α/β treatment of macrophages induced
the expression of the HIV restriction miRNAs (Zhou et al.,
2010). We also reported that morphine treatment of monocytes
could inhibit the expression of several HIV restriction miRNAs
(Wang et al., 2011a). Studies by others showed that morphine
suppressed IFN-α expression in PBMCs and T lymphocytes
(Nair et al., 1997; Homan et al., 2002). In addition, morphine
suppresses Sendai virus-induced IFN-α production by PBMCs
(Nair et al., 1997). These ﬁndings support our observation that
heroin could downregulate IFN-α/β expression in macrophages
(Figure 5).
CONCLUSION
Our study provides the compelling evidence that heroin enhances
HIV replication in macrophages through the inhibition of the
intracellular HIV restriction miRNAs. These ﬁndings support
the notion that opioids compromise speciﬁc host innate defense
mechanisms against HIV infection. Understanding how heroin
abuse impairs speciﬁc immune responses to HIV infection
should improve and advance our ability to treat HIV-infected
heroin users. Nevertheless, future studies are necessary to
reveal additional and unidentiﬁed mechanisms by which heroin
damages the intracellular innate immunity that controls HIV in
CD4+ T cells and macrophages.
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